On September 17, 2018 VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, reported that the company will provide a corporate overview at two events during October, as detailed below (Press release, VBL Therapeutics, SEP 17, 2018, View Source [SID1234529459]). In addition the Company will present data on its novel MOSPD2 program at ECTRIMS 2018 – European Committee for Treatment and Research in Multiple Sclerosis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Fitzgerald Global Healthcare Conference – Presentation Details
Date: Wednesday, October 3, 2018
Time: 10:20am Eastern Time
Location: InterContinental New York Barclay Hotel, New York
Webcast: View Source

Chardan Gene Therapy Conference – Presentation Details
Date: Tuesday, October 9, 2018
Time: 1:30pm Eastern Time
Location: Westin Grand Central Hotel, New York
Webcast: View Source

ECTRIMS 2018 – Poster Presentation Details:
Abstract: MOSPD2: A Novel Therapeutic Target for the Treatment of CNS Inflammation
Session title: Poster Session 2
Date: Thursday, October 11, 2018
Time: 5:15-7:15pm Central European Summer Time
Poster #: P871
Location: City Cube Messe Berlin